Targeting cartilage regeneration in joint and intervertebral disc diseases
A consortium that combines novel highly advanced drug delivery carriers with dedicated targeting tools, state-of-the-art imaging techniques and expertise in stem cell and joint biology.
15 young scientists, 15 partner institutions, 5 different countries.
What do we do?
The TargetCaRe consortium aims to develop treatments for joint and intervertebral disc diseases by combining advanced drug delivery carriers with dedicated targeting tools, state of the art imaging techniques and expertise in biology of stem cells and joints.
Who are we?
The TargetCaRe consortium consists of world-leading scientists from 14 institutions in 5 countries. All scientists are renown experts in their field of research, such as stem cell biology, biomaterial technology, in vivo imaging, nanomedicine and mass spectrometry imaging.